| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1046023103 |
| P356 | DOI | 10.1038/NRC2731 |
| P698 | PubMed publication ID | 19776746 |
| P2093 | author name string | Guillermina Lozano | |
| Lawrence A Donehower | |||
| P2860 | cites work | Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations | Q27730815 |
| p53, the cellular gatekeeper for growth and division | Q27860990 | ||
| WAF1, a potential mediator of p53 tumor suppression | Q27861121 | ||
| Surfing the p53 network | Q28032484 | ||
| Rescue of embryonic lethality in Mdm4-null mice by loss of Trp53 suggests a nonoverlapping pathway with MDM2 to regulate p53 | Q28214793 | ||
| p53 regulates maternal reproduction through LIF | Q28259206 | ||
| Altering the genome by homologous recombination | Q28270159 | ||
| p73-deficient mice have neurological, pheromonal and inflammatory defects but lack spontaneous tumours | Q28513003 | ||
| p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development | Q28587664 | ||
| p63 is a p53 homologue required for limb and epidermal morphogenesis | Q28588206 | ||
| p63 deficiency activates a program of cellular senescence and leads to accelerated aging | Q28592969 | ||
| Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours | Q29547697 | ||
| Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53 | Q29614430 | ||
| The consequence of p53 overexpression for liver tumor development and the response of transformed murine hepatocytes to genotoxic agents. | Q40865245 | ||
| The p53-deficient mouse: a model for basic and applied cancer studies | Q41436922 | ||
| Gain of function mutations in p53. | Q41557652 | ||
| Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome | Q41816411 | ||
| Ser18 and 23 phosphorylation is required for p53-dependent apoptosis and tumor suppression | Q42062886 | ||
| Temporal dissection of p53 function in vitro and in vivo | Q44365729 | ||
| Mdm2 is critically and continuously required to suppress lethal p53 activity in vivo. | Q44896717 | ||
| p53 must be competent for transcriptional regulation to suppress tumor formation | Q45306125 | ||
| Prostate-specific expression of p53(R172L) differentially regulates p21, Bax, and mdm2 to inhibit prostate cancer progression and prolong survival. | Q45871432 | ||
| The p53QS transactivation-deficient mutant shows stress-specific apoptotic activity and induces embryonic lethality | Q46111122 | ||
| p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM. | Q46200576 | ||
| Somatic mutation of p53 leads to estrogen receptor alpha-positive and -negative mouse mammary tumors with high frequency of metastasis | Q46557073 | ||
| Mice expressing a mammary gland-specific R270H mutation in the p53 tumor suppressor gene mimic human breast cancer development. | Q46706112 | ||
| The ataxia telangiectasia-mutated target site Ser18 is required for p53-mediated tumor suppression | Q46843477 | ||
| Cloning of senescent cell-derived inhibitors of DNA synthesis using an expression screen | Q48084448 | ||
| Cancer phenotype correlates with constitutional TP53 genotype in families with the Li-Fraumeni syndrome | Q48379673 | ||
| High-frequency developmental abnormalities in p53-deficient mice. | Q52206956 | ||
| A teratologic suppressor role for p53 in benzo(a)pyrene–treated transgenic p53-deficient mice | Q52207983 | ||
| Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer | Q52544495 | ||
| Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome | Q52561781 | ||
| Selective evolution of stromal mesenchyme with p53 loss in response to epithelial tumorigenesis | Q52567811 | ||
| The p53 family in differentiation and tumorigenesis. | Q53336172 | ||
| Lung-specific expression of human mutant p53-273H is associated with a high frequency of lung adenocarcinoma in transgenic mice | Q53385488 | ||
| Knock-in mice with a chimeric human/murine p53 gene develop normally and show wild-type p53 responses to DNA damaging agents: a new biomedical research tool | Q53399551 | ||
| Reduction of p53 gene dosage does not increase initiation or promotion but enhances malignant progression of chemically induced skin tumors | Q53478233 | ||
| Thymocyte apoptosis induced by p53-dependent and independent pathways | Q54242475 | ||
| p53 tumour suppressor gene polymorphism is associated with recurrent implantation failure. | Q54579010 | ||
| Reduced latency but no increased brain tumor penetrance in mice with astrocyte specific expression of a human p53 mutant. | Q55474891 | ||
| The price of tumour suppression? | Q56672523 | ||
| Delayed ageing through damage protection by the Arf/p53 pathway | Q57562759 | ||
| Tumour incidence, spectrum and ploidy in mice with a large deletion in the p53 gene | Q58423654 | ||
| Spontaneous Squamous Cell Carcinoma Induced by the Somatic Inactivation of Retinoblastoma and Trp53 Tumor Suppressors | Q63884137 | ||
| Loss of heterozygosity occurs via mitotic recombination in Trp53+/- mice and associates with mammary tumor susceptibility of the BALB/c strain | Q64388914 | ||
| p53-dependent apoptosis suppresses radiation-induced teratogenesis | Q71046591 | ||
| Enhanced proliferative potential in culture of cells from p53-deficient mice | Q71600264 | ||
| Wild-type p53 transgenic mice exhibit altered differentiation of the ureteric bud and possess small kidneys | Q71627486 | ||
| A subset of p53-deficient embryos exhibit exencephaly | Q72031963 | ||
| p53-dependent apoptosis suppresses tumor growth and progression in vivo | Q72149266 | ||
| Preferential overexpression of a 172Arg-->Leu mutant p53 in the mammary gland of transgenic mice results in altered lobuloalveolar development | Q72772605 | ||
| Genetic background alters the spectrum of tumors that develop in p53-deficient mice | Q72864214 | ||
| Apoptosis or retinoblastoma: alternative fates of photoreceptors expressing the HPV-16 E7 gene in the presence or absence of p53 | Q72871721 | ||
| The loss of mdm2 induces p53-mediated apoptosis | Q73673966 | ||
| A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy | Q74117541 | ||
| mdmx is a negative regulator of p53 activity in vivo | Q74198977 | ||
| The mouse equivalent of the human p53ser249 mutation p53ser246 enhances aflatoxin hepatocarcinogenesis in hepatitis B surface antigen transgenic and p53 heterozygous null mice | Q74428413 | ||
| Chromosome stability, in the absence of apoptosis, is critical for suppression of tumorigenesis in Trp53 mutant mice | Q75217030 | ||
| Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome | Q81166001 | ||
| Genetic mapping of a third Li-Fraumeni syndrome predisposition locus to human chromosome 1q23 | Q81369426 | ||
| Tumor predisposition in mice mutant for p63 and p73: evidence for broader tumor suppressor functions for the p53 family | Q81662172 | ||
| Loss of one but not two mdm2 null alleles alters the tumour spectrum in p53 null mice | Q93924394 | ||
| Regulating the p53 pathway: in vitro hypotheses, in vivo veritas | Q29615658 | ||
| Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas | Q29616243 | ||
| Tumor spectrum analysis in p53-mutant mice | Q29617436 | ||
| Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53 | Q29617850 | ||
| Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms | Q29618586 | ||
| Restoration of p53 function leads to tumour regression in vivo | Q29618727 | ||
| Effects of an Rb mutation in the mouse | Q29619196 | ||
| Mice deficient for Rb are nonviable and show defects in neurogenesis and haematopoiesis | Q29619200 | ||
| p53 is required for radiation-induced apoptosis in mouse thymocytes | Q29620281 | ||
| p53 mutant mice that display early ageing-associated phenotypes | Q29622826 | ||
| Modulation of mammalian life span by the short isoform of p53. | Q30312095 | ||
| Long-term haematopoietic reconstitution by Trp53-/-p16Ink4a-/-p19Arf-/- multipotent progenitors | Q33328820 | ||
| Timed somatic deletion of p53 in mice reveals age-associated differences in tumor progression | Q33493417 | ||
| p53 regulates hematopoietic stem cell quiescence. | Q33732098 | ||
| p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation | Q33733341 | ||
| Retention of wild-type p53 in tumors from p53 heterozygous mice: reduction of p53 dosage can promote cancer formation | Q33889285 | ||
| The C-terminal lysines fine-tune P53 stress responses in a mouse model but are not required for stability control or transactivation | Q33900545 | ||
| Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome. | Q33931140 | ||
| Dial 9-1-1 for p53: mechanisms of p53 activation by cellular stress | Q33997846 | ||
| Telomerase reverse transcriptase delays aging in cancer-resistant mice | Q34014691 | ||
| Targeted point mutations of p53 lead to dominant-negative inhibition of wild-type p53 function | Q34015423 | ||
| Cellular senescence: mitotic clock or culture shock? | Q34019131 | ||
| Germline TP53 mutations and Li-Fraumeni syndrome | Q34181585 | ||
| Alpha-inhibin is a tumour-suppressor gene with gonadal specificity in mice | Q34263387 | ||
| Involvement of p53-dependent apoptosis in radiation teratogenesis and in the radioadaptive response in the late organogenesis of mice | Q34274548 | ||
| Tumor suppression and normal aging in mice with constitutively high p53 activity | Q34324057 | ||
| Spontaneous and carcinogen-induced tumorigenesis in p53-deficient mice. | Q34347328 | ||
| "Super p53" mice exhibit enhanced DNA damage response, are tumor resistant and age normally | Q34369829 | ||
| Is p53 Haploinsufficient for Tumor Suppression? Implications for the p53+/- Mouse Model in Carcinogenicity Testing | Q34429238 | ||
| The p53 proto-oncogene can act as a suppressor of transformation | Q34440370 | ||
| The pathological response to DNA damage does not contribute to p53-mediated tumour suppression | Q34564198 | ||
| The regulation of INK4/ARF in cancer and aging | Q34575801 | ||
| Modeling the therapeutic efficacy of p53 restoration in tumors | Q34593294 | ||
| Crippling p53 activities via knock-in mutations in mouse models | Q34614596 | ||
| p63 heterozygous mutant mice are not prone to spontaneous or chemically induced tumors. | Q34694274 | ||
| Rapid generation of inducible mouse mutants | Q34771977 | ||
| Acetylation of mouse p53 at lysine 317 negatively regulates p53 apoptotic activities after DNA damage | Q35071254 | ||
| p21 delays tumor onset by preservation of chromosomal stability | Q35225097 | ||
| Phosphorylation of serine 18 regulates distinct p53 functions in mice | Q35545143 | ||
| The impact of altered p53 dosage on hematopoietic stem cell dynamics during aging | Q35628919 | ||
| High metastatic potential in mice inheriting a targeted p53 missense mutation | Q35673678 | ||
| Genetic manipulation of the mouse via gene targeting in embryonic stem cells | Q35784859 | ||
| Development of spontaneous mammary tumors in BALB/c p53 heterozygous mice. A model for Li-Fraumeni syndrome | Q35829654 | ||
| Osteoblast differentiation and skeletal development are regulated by Mdm2-p53 signaling | Q36117276 | ||
| Probing p53 biological functions through the use of genetically engineered mouse models | Q36204567 | ||
| p63: oncogene or tumor suppressor? | Q36344444 | ||
| Dissecting p53 tumor suppressor function in vivo through the analysis of genetically modified mice | Q36430180 | ||
| Knockin mice expressing a chimeric p53 protein reveal mechanistic differences in how p53 triggers apoptosis and senescence | Q36446127 | ||
| neu/ERBB2 cooperates with p53-172H during mammary tumorigenesis in transgenic mice | Q36568624 | ||
| The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss | Q36649149 | ||
| The oncogenic roles of p53 mutants in mouse models | Q36701574 | ||
| Tumor suppressor dosage regulates stem cell dynamics during aging | Q36716337 | ||
| Conditional mouse osteosarcoma, dependent on p53 loss and potentiated by loss of Rb, mimics the human disease | Q36720962 | ||
| Coping with stress: multiple ways to activate p53. | Q36745375 | ||
| High incidence of lung, bone, and lymphoid tumors in transgenic mice overexpressing mutant alleles of the p53 oncogene | Q36760672 | ||
| Cancer and ageing: convergent and divergent mechanisms | Q36918634 | ||
| TAp73 knockout shows genomic instability with infertility and tumor suppressor functions | Q36919913 | ||
| Metastatic osteosarcoma induced by inactivation of Rb and p53 in the osteoblast lineage | Q36954453 | ||
| p53 Family isoforms | Q37090171 | ||
| The impact of p53 and p73 on aneuploidy and cancer | Q37136283 | ||
| p53: a new player in reproduction | Q37138983 | ||
| The jury is in: p73 is a tumor suppressor after all. | Q37285304 | ||
| p53 and MDM2: antagonists or partners in crime? | Q37403313 | ||
| Mutation and childhood cancer: a probabilistic model for the incidence of retinoblastoma | Q37466499 | ||
| Mdm2-mediated ubiquitylation: p53 and beyond. | Q37508606 | ||
| Defective apoptosis and B-cell lymphomas in mice with p53 point mutation at Ser 23. | Q37524264 | ||
| Increased sensitivity to UV radiation in mice with a p53 point mutation at Ser389. | Q37527427 | ||
| When mutants gain new powers: news from the mutant p53 field. | Q37582777 | ||
| p53 and E2f: partners in life and death | Q37602510 | ||
| Genetics of human cancer | Q39461610 | ||
| Germ-line transformation of mice | Q39757195 | ||
| Induction of medulloblastomas in p53-null mutant mice by somatic inactivation of Rb in the external granular layer cells of the cerebellum | Q40442891 | ||
| P433 | issue | 11 | |
| P304 | page(s) | 831-841 | |
| P577 | publication date | 2009-09-24 | |
| P13046 | publication type of scholarly work | review article | Q7318358 |
| P1433 | published in | Nature Reviews Cancer | Q641657 |
| P1476 | title | 20 years studying p53 functions in genetically engineered mice | |
| P478 | volume | 9 |
| Q35680216 | A Genetic Porcine Model of Cancer |
| Q34148472 | A High-Frequency Regulatory Polymorphism in the p53 Pathway Accelerates Tumor Development |
| Q35108867 | A p53/ARF-dependent anticancer barrier activates senescence and blocks tumorigenesis without impacting apoptosis |
| Q50225374 | Atf3 deficiency promotes genome instability and spontaneous tumorigenesis in mice |
| Q47265220 | Cardiac-specific ablation of the E3 ubiquitin ligase Mdm2 leads to oxidative stress, broad mitochondrial deficiency and early death |
| Q33825155 | Characterization of functional domains necessary for mutant p53 gain of function |
| Q41380246 | Coamplification of Myc/Pvt1 and homozygous deletion of Nlrp1 locus are frequent genetics changes in mouse osteosarcoma. |
| Q46056223 | Combination analysis of Bub1 and Mad2 expression in endometrial cancer: act as a prognostic factor in endometrial cancer |
| Q90699144 | Context is everything: extrinsic signalling and gain-of-function p53 mutants |
| Q58805589 | Control of metabolism by p53 - Cancer and beyond |
| Q43400614 | Cytoplasmic E3 ubiquitin ligase CUL9 controls cell proliferation, senescence, apoptosis and genome integrity through p53. |
| Q35739649 | Decrease of mitochondrial p53 during late apoptosis is linked to its dephosphorylation on serine 20 |
| Q64376947 | Degradation of DAXX by adenovirus type 12 E1B-55K circumvents chemoresistance of ovarian cancer to cisplatin |
| Q39456771 | Derisking Drug-Induced Carcinogenicity for Novel Therapeutics |
| Q48267805 | Desumoylase SENP6 maintains osteochondroprogenitor homeostasis by suppressing the p53 pathway. |
| Q27003153 | Deubiquitinating enzyme regulation of the p53 pathway: A lesson from Otub1 |
| Q36556345 | Dietary downregulation of mutant p53 levels via glucose restriction: mechanisms and implications for tumor therapy |
| Q36823657 | Dissecting the pathways that destabilize mutant p53: The proteasome or autophagy? |
| Q42246401 | Dmp1 physically interacts with p53 and positively regulates p53's stability, nuclear localization, and function |
| Q26766173 | Dysregulation of microRNA biogenesis in cancer: the impact of mutant p53 on Drosha complex activity |
| Q42039942 | Efficacy of targeted AKT inhibition in genetically engineered mouse models of PTEN-deficient prostate cancer |
| Q47094378 | Efficient generation of P53 biallelic knockout Diannan miniature pigs via TALENs and somatic cell nuclear transfer |
| Q58728912 | Emergence of Members of TRAF and DUB of Ubiquitin Proteasome System in the Regulation of Hypertrophic Cardiomyopathy |
| Q28077156 | Emerging Non-Canonical Functions and Regulation by p53: p53 and Stemness |
| Q90246026 | Epithelial Cell Cycle Behaviour in the Injured Kidney |
| Q46234676 | Ferredoxin reductase is critical for p53-dependent tumor suppression via iron regulatory protein 2. |
| Q37381590 | Fischer-344 Tp53-knockout rats exhibit a high rate of bone and brain neoplasia with frequent metastasis. |
| Q35273347 | Functional repair of p53 mutation in colorectal cancer cells using trans-splicing |
| Q34036181 | Gene expression profiling of mouse p53-deficient epidermal carcinoma defines molecular determinants of human cancer malignancy |
| Q33921220 | Generation and characterization of a JAK2V617F-containing erythroleukemia cell line |
| Q57799376 | Generation of a TP53-modified porcine cancer model by CRISPR/Cas9-mediated gene modification in porcine zygotes via electroporation |
| Q35921166 | Generation of primary tumors with Flp recombinase in FRT-flanked p53 mice |
| Q35067979 | Genetic prevention of lymphoma in p53 knockout mice allows the early development of p53-related sarcomas |
| Q33892356 | Genomic instability, defective spermatogenesis, immunodeficiency, and cancer in a mouse model of the RIDDLE syndrome |
| Q50286692 | Haploinsufficiency of Trp53 dramatically extends the lifespan of Sirt6-deficient mice |
| Q28484241 | Inactivation and inducible oncogenic mutation of p53 in gene targeted pigs |
| Q50083521 | Inactivation of the MDM2 RING domain enhances p53 transcriptional activity in mice |
| Q35140413 | Inhibition of p53 by Adenovirus Type 12 E1B-55K Deregulates Cell Cycle Control and Sensitizes Tumor Cells to Genotoxic Agents |
| Q38177769 | Insights into wild-type and mutant p53 functions provided by genetically engineered mice |
| Q42553511 | Intraperitoneal oxidative stress as an oncolytic immunomodulator? |
| Q33627910 | It's all about balance: p53 and aging |
| Q42386107 | JAK2V617F and p53 mutations coexist in erythroleukemia and megakaryoblastic leukemic cell lines |
| Q28260776 | Jdp2 downregulates Trp53 transcription to promote leukaemogenesis in the context of Trp53 heterozygosity |
| Q28274115 | LNK/SH2B3 regulates IL-7 receptor signaling in normal and malignant B-progenitors |
| Q28277689 | Linking functional decline of telomeres, mitochondria and stem cells during ageing |
| Q37018237 | Loss of PML cooperates with mutant p53 to drive more aggressive cancers in a gender-dependent manner |
| Q35059874 | Mad2 is a critical mediator of the chromosome instability observed upon Rb and p53 pathway inhibition. |
| Q34503497 | Making sense of ubiquitin ligases that regulate p53 |
| Q38016717 | Mdm2 and MdmX partner to regulate p53 |
| Q39029101 | Mechanisms of p53 Functional De-Regulation: Role of the IκB-α/p53 Complex |
| Q90424331 | Mouse bone marrow mesenchymal stem cells with distinct p53 statuses display differential characteristics |
| Q33752174 | Mouse models of p53 functions |
| Q33818479 | Mutant TP53 posttranslational modifications: challenges and opportunities. |
| Q38204111 | Mutant p53 exerts oncogenic effects through microRNAs and their target gene networks |
| Q64892305 | Mutant p53 in cancer therapy-the barrier or the path. |
| Q55026448 | Mutant p53 inhibits miRNA biogenesis by interfering with the microprocessor complex. |
| Q36070574 | Mutant p53: one name, many proteins |
| Q38921006 | NKD2, a negative regulator of Wnt signaling, suppresses tumor growth and metastasis in osteosarcoma |
| Q38389967 | New perspective on targeting the tumor suppressor p53 pathway in the tumor microenvironment to enhance the efficacy of immunotherapy. |
| Q34720933 | Noncanonical Wnt signaling mediates androgen-dependent tumor growth in a mouse model of prostate cancer |
| Q37971404 | Novel roles of Skp2 E3 ligase in cellular senescence, cancer progression, and metastasis |
| Q34149922 | Oncogenes and tumor suppressor genes |
| Q92999963 | Oncogenic RUNX3: A Link between p53 Deficiency and MYC Dysregulation |
| Q38215948 | Oncogenic roles of EMT-inducing transcription factors |
| Q30389604 | Pharmacological reactivation of mutant p53: from protein structure to the cancer patient |
| Q39225715 | RLIP76 Inhibition: A Promising Developmental Therapy for Neuroblastoma |
| Q34774518 | RXRα ablation in epidermal keratinocytes enhances UVR-induced DNA damage, apoptosis, and proliferation of keratinocytes and melanocytes. |
| Q42400885 | Rapamycin as longevity enhancer and cancer preventative agent in the context of p53 deficiency |
| Q36401948 | Rats deficient for p53 are susceptible to spontaneous and carcinogen-induced tumorigenesis |
| Q39424924 | Regulation of the Mdm2-p53 signaling axis in the DNA damage response and tumorigenesis |
| Q52724571 | Rlip depletion prevents spontaneous neoplasia in TP53 null mice |
| Q35092610 | Serine 312 phosphorylation is dispensable for wild-type p53 functions in vivo |
| Q38838490 | Stabilization of the p53-DNA Complex by the Nuclear Protein Dmp1α. |
| Q39747547 | Structure- and ligand-based virtual screening identifies new scaffolds for inhibitors of the oncoprotein MDM2. |
| Q34326278 | Synergistic interaction of Rnf8 and p53 in the protection against genomic instability and tumorigenesis. |
| Q37894331 | TP53 Mutations in Human Cancer: Database Reassessment and Prospects for the Next Decade |
| Q83080803 | TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome |
| Q38507513 | TP53: an oncogene in disguise. |
| Q38059739 | Targeting the Ubiquitin-Mediated Proteasome Degradation of p53 for Cancer Therapy |
| Q27010154 | The BCL2 Family: Key Mediators of the Apoptotic Response to Targeted Anticancer Therapeutics |
| Q34109150 | The BRCA1-interacting protein Abraxas is required for genomic stability and tumor suppression. |
| Q42322261 | The HERC2 ubiquitin ligase is essential for embryonic development and regulates motor coordination. |
| Q37225303 | The consequence of oncomorphic TP53 mutations in ovarian cancer |
| Q33668469 | The dichotomy of p53 regulation by noncoding RNAs |
| Q38786667 | The importance of p53 pathway genetics in inherited and somatic cancer genomes. |
| Q34096437 | The influence of Trp53 in the dose response of radiation-induced apoptosis, DNA repair and genomic stability in murine haematopoietic cells |
| Q90183526 | The specific seroreactivity to ∆Np73 isoforms shows higher diagnostic ability in colorectal cancer patients than the canonical p73 protein |
| Q39679838 | The ups and downs of p53 regulation in hematopoietic stem cells |
| Q35688431 | The use of genetically modified mice in cancer risk assessment: challenges and limitations. |
| Q83600797 | Tissue-specific microRNA expression alters cancer susceptibility conferred by a TP53 noncoding variant |
| Q34100529 | Tracing the protectors path from the germ line to the genome |
| Q35138721 | Trans-splicing repair of mutant p53 suppresses the growth of hepatocellular carcinoma cells in vitro and in vivo |
| Q57494129 | Transglutaminase-2 promotes metastatic and stem-like phenotypes in osteosarcoma |
| Q36455302 | Two distinct knockout approaches highlight a critical role for p53 in rat development |
| Q59123044 | Ubiquitin ligase RNF8 suppresses Notch signaling to regulate mammary development and tumorigenesis |
| Q35177312 | Uncoupling Cancer Mutations Reveals Critical Timing of p53 Loss in Sarcomagenesis |
| Q38059699 | Using Mouse Models to Explore MDM-p53 Signaling in Development, Cell Growth, and Tumorigenesis |
| Q37623308 | YAP enhances the pro-proliferative transcriptional activity of mutant p53 proteins |
| Q39490746 | miR-100 antagonism triggers apoptosis by inhibiting ubiquitination-mediated p53 degradation |
| Q36648035 | p53 Regulates Neural Stem Cell Proliferation and Differentiation via BMP-Smad1 Signaling and Id1 |
| Q30424916 | p53 and microRNA-34 are suppressors of canonical Wnt signaling. |
| Q34029735 | p53 at a glance |
| Q37793657 | p53 connects tumorigenesis and reprogramming to pluripotency |
| Q38366523 | p53, a translational regulator: contribution to its tumour-suppressor activity. |
| Q37727778 | p53-family proteins and their regulators: hubs and spokes in tumor suppression |
Search more.